December 25, 2024 11:43 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Former home secy Ajay Kumar Bhalla appointed Manipur Guv amid ethnic violence resurgence | Five soldiers killed, several injured as Army truck falls into Poonch gorge | Allu Arjun quizzed by police in Pushpa 2 stampede case | Wanted Indian drug smuggler killed in the US | Congress leader files complaint against Allu Arjun for 'insulting police' in Pushpa 2: The Rule | Ahead of Jaishankar's US visit, foreign secretary Vikram Misri meets top US diplomats | India refrains from commenting on extradition request for ousted Bengladeshi PM Sheikh Hasina | I don't blame Allu Arjun, ready to withdraw case: Pushpa 2 stampede victim's husband | Indian New Wave Cinema Architect Shyam Benegal dies at age 90 | Cylinder blast at a temple in Karnataka's Hubbali injures nine people

GVK BIO announces completion of drug repurposing efforts

| | Oct 22, 2014, at 02:33 am
Kolkata, Oct 21 (IBNS): GVK Biosciences (GVK BIO), Asia's leading integrated Discovery Research and Development organization on Tuesday announced the successful completion of in-silico based alternative indications of shelved compounds for Takeda Pharmaceutical Company Limited using GVK BIO's proprietary Drug Repurposing Platform.

Taking the project to the next level GVK BIO and Takeda have jointly agreed to evaluate the pre-clinical proof-of-concept for certain indications of selected therapeutic compounds to develop novel indications for the previously failed compounds.

Having worked for over a decade with global majors in the Pharmaceutical industry GVK BIO has leveraged its experience and expertise in Drug Discovery and has developed a unique Drug Repurposing Platform called GRIP (GVK BIO Repurposing Integrated Platform).

GRIP is a combination of proprietary Repurposing Database, Eight different repurposing algorithms, Analytics tools and Visualization engine.

The Repurposing database consists of more than 45+ databases which enable the relationship between Drug-Target-Disease. 

Drug repurposing algorithms allow for unbiased interpretation of the input data to predict alternative indications. GVK BIO’s value proposition in Drug Repurposing is that it offers in-silico analysis as well as pre-clinical support to execute projects and establish proof of concept.

Nandu Gattu, Vice President -Drug Repurposing at GVK BIO said, “GVK BIO is well known for its rich and extensive biological, chemical and clinical databases. A marriage between computational algorithms, analytical capabilities and our custom curated databases along with proven drug discovery experience enables us to develop a multi-pronged approach resulting in higher success rates.”

Sreeni Devidas, Vice President Business Development at GVK BIO said, “GVK BIO has leveraged its expertise in Informatics to successfully build it Drug Repositioning Platform. The success with Takeda illustrates the value add that this approach brings to enhancing the pipeline of our customers and collaborators.”
 

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.